<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet aggregation activities</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--except for validated indications for this combination in acute coronary syndromes.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="">
<ATC code="1037042" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPRVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Doubling of the plasma concentrations of the antiagregant, with risk of increase of its undesirable effects, especially hemorrhagic ones</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>518-TICAGRELOR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
